의료기기 이야기

Background on eSTARThe electronic submission template and resource (eSTAR) template can be used to submit US FDA Premarket Notifications (510(k)s), De Novos, and Traditional Premarket Applications (PMAs). eSTAR was compulsory for 510(k) submissions starting in October 2023. eSTAR will be required for De Novos starting in October 2025.eSTAR version 5.5eSTAR Version 5.5 was released (February 12)...

The United States Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) recently released its 2024 Annual Report (link currently broken, but we will post once available from CDRH) highlighting some of its achievements over the past year. This is a summary of the main topics.The US FDA CDRH in 2024The CDRH is responsible for regulating medical devices in the U.S. It..

Emergo에서 아래와 같이 웨비나를 개최한다.​▶ 주제: Determining when to utilize the pre-submissions Q-submission (Pre-Sub) Process▶ 일시: 2025년 02월 12일 CST 9시 (한국시간: 02월 13일 00시) In many cases, a manufacturer must submit a marketing submission (such as a 510(k)) to the U.S. Food and Drug Administration (FDA) and have it authorized before they can start selling that device in the U.S. But what if a manufacturer has q..

On November 30, 2023, the FDA announced in the Federal Register its intention to classify certain types of wound dressings that had remained unclassified as pre-amendment devices; i.e., devices that were in commercial distribution before enactment of the Medical Device Amendments of May 28, 1976. The specific wound dressings the FDA is proposing to classify fall into the following three distinct..

FDA updated of the list of cleared or approved companion diagnostic devices (in vitro and imaging tools). - Device: CRCDx RAS mutation detection assay kit - Generic name: somatic gene mutation detection system - Applicant: EntroGen, Inc - PMA number: P220005 - Approval order statement Approval for the CRCdx® RAS Mutation Detection Kit. The device is a qualitative real-time PCR in vitro diagnosti..